BIOA
BioAge Labs, Inc. NASDAQ Listed Sep 26, 2024$20.77
+3.90%
vs $19.99
Mkt Cap $746.3M
52w Low $4.12
88.6% of range
52w High $22.92
50d MA $17.38
200d MA $14.00
P/E (TTM)
-9.3x
EV/EBITDA
—
P/B
2.7x
Debt/Equity
0.0x
ROE
-29.6%
P/FCF
-9.1x
RSI (14)
66.40
ATR (14)
$1.34
Beta
1.83
50d MA
$17.38
200d MA
$14.00
Avg Volume
430.7K
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets allows users to identify targets based on insights into molecular changes that drive aging. Its product includes azelaprag, an orally available small molecule that is in phase 1 clinical trial for the treatment of obesity; and initiated phase 2 clinical trial of azelaprag in combination with tirzepatide for the treatment of obesity in older adults. It also develops BGE-100, an orally available small molecule brain-penetrant NLRP3 antagonist for the treatment of diseases driven by neuroinflammation. The company was incorporated in 2015 and is based in Richmond, California.
CIK (SEC)
Phone
510 806 1445
1445A South 50th Street · Emeryville, CA 94804 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 8, 2026 | BMO | — | — | — | 17.82 | -1.7% | +1.0% | +0.9% | +0.2% | +5.2% | -2.2% | — |
| May 7, 2026 | BMO | — | — | — | 18.46 | -0.5% | -3.5% | +1.0% | +0.9% | +0.2% | +5.2% | — |
| Mar 24, 2026 | BMO | -0.83 | -0.72 | +13.3% | 16.11 | +1.1% | +1.9% | +0.0% | -1.0% | -0.6% | -2.0% | — |
| Nov 6, 2025 | BMO | -0.67 | -0.56 | +16.4% | 7.47 | -2.7% | -2.8% | +0.0% | +3.2% | +4.5% | +2.3% | — |
| Aug 6, 2025 | BMO | -0.56 | -0.60 | -7.1% | 4.33 | +1.8% | -0.2% | +0.0% | +0.2% | +0.2% | +3.2% | — |
| May 6, 2025 | BMO | -0.52 | -0.36 | +30.8% | 3.95 | +0.8% | +2.8% | +0.0% | +1.2% | -1.7% | +0.7% | — |
| Mar 20, 2025 | BMO | -0.58 | -1.97 | -239.7% | 4.38 | -3.2% | +2.5% | +0.0% | +1.1% | -5.7% | -6.8% | — |
| Nov 7, 2024 | BMO | -0.72 | -6.70 | -830.6% | 20.62 | +1.1% | +7.6% | +0.0% | +2.2% | -11.8% | +0.9% | — |
| Sep 26, 2024 | BMO | — | -1.80 | — | 18.31 | +5.4% | +14.7% | +0.0% | -1.0% | -2.6% | -2.6% | — |
| Mar 31, 2024 | BMO | — | -1.74 | — | — | — | — | — | — | — | — | — |
| Dec 31, 2023 | BMO | — | -2.81 | — | — | — | — | — | — | — | — | — |
| Sep 30, 2023 | BMO | — | -1.96 | — | — | — | — | — | — | — | — | — |
| Jun 30, 2023 | BMO | — | -2.30 | — | — | — | — | — | — | — | — | — |
| Mar 31, 2023 | BMO | — | -1.48 | — | — | — | — | — | — | — | — | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 27 | Roth Capital | Initiates | Buy | $36 | $16.20 | $16.78 | +3.6% | +4.6% | +0.6% | +1.4% | -0.5% | -3.8% |
| May 13 | BTIG Research | Initiates | Buy | $40 | $18.19 | $18.55 | +2.0% | +5.2% | -2.2% | -5.7% | -13.1% | +6.7% |
| Mar 10 | Citigroup | Maintains | Buy → Buy | — | $19.73 | $20.37 | +3.2% | +6.3% | -4.3% | -0.9% | -5.9% | +15.1% |
| Feb 18 | Jefferies | Upgrade | Hold → Buy | — | $19.63 | $21.40 | +9.0% | -0.2% | +2.8% | +1.8% | +4.1% | +1.0% |
| Dec 8 | Morgan Stanley | Upgrade | Underweight → Equal Weight | — | $11.61 | $11.35 | -2.2% | +1.9% | +1.9% | +5.1% | +0.6% | +1.0% |
| Oct 29 | Citigroup | Maintains | Buy → Buy | — | $7.89 | $8.00 | +1.4% | -2.7% | +0.7% | -2.1% | -2.0% | +0.7% |
| Oct 22 | Citigroup | Upgrade | Neutral → Buy | — | $5.30 | $5.69 | +7.4% | +14.2% | +31.4% | -4.4% | +0.4% | +3.4% |
| Mar 24 | Citigroup | Maintains | Neutral → Neutral | — | $4.49 | $4.37 | -2.7% | +1.1% | -5.7% | -6.8% | -2.8% | -1.5% |
| Dec 9 | Citigroup | Downgrade | Buy → Neutral | — | $20.09 | $5.65 | -71.9% | -76.9% | -3.9% | +7.4% | -4.4% | -6.8% |
| Dec 9 | Jefferies | Downgrade | Buy → Hold | — | $20.09 | $5.65 | -71.9% | -76.9% | -3.9% | +7.4% | -4.4% | -6.8% |
No insider trades available.
8-K
BioAge Labs, Inc. -- 8-K Filing
Jun 12
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
This vague 8-K provides no material disclosure details, leaving investors unable to assess what information BIOA management disclosed or its implications for the company's valuation and operations.
Mar 24
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Janus Henderson Group Plc | 2,094,270 | $37M | New | Mar 2026 |
| 2 | Vanguard Capital Management Llc | 1,354,906 | $24M | New | Mar 2026 |
| 3 | Sands Capital Alternatives, Llc | 786,353 | $14M | — | Mar 2026 |
| 4 | D.e. Shaw & Co | 699,190 | $12M | Added | Mar 2026 |
| 5 | Morgan Stanley | 623,318 | $8M | Added | Dec 2025 |
| 6 | Millennium Management | 430,463 | $8M | Added | Mar 2026 |
| 7 | Acadian Asset Management Llc | 392,346 | $7M | Added | Mar 2026 |
| 8 | Stempoint Capital Lp | 338,654 | $6M | New | Mar 2026 |
| 9 | Walleye Capital Llc | 303,348 | $5M | Added | Mar 2026 |
| 10 | Vanguard Portfolio Management Llc | 286,946 | $5M | New | Mar 2026 |
| 11 | Franklin Resources Inc | 265,373 | $5M | New | Mar 2026 |
| 12 | Northern Trust Corp | 224,129 | $4M | Added | Mar 2026 |
| 13 | Y-Intercept (Hong Kong) Ltd | 201,337 | $4M | New | Mar 2026 |
| 14 | Marshall Wace, Llp | 190,472 | $3M | Reduced | Mar 2026 |
| 15 | Fmr Llc | 190,298 | $3M | Added | Mar 2026 |
| 16 | Invesco Ltd. | 176,110 | $3M | Reduced | Mar 2026 |
| 17 | Ensign Peak Advisors, Inc | 166,224 | $3M | New | Mar 2026 |
| 18 | Jpmorgan Chase & Co | 173,570 | $3M | Added | Mar 2026 |
| 19 | Renaissance Technologies Llc | 138,588 | $2M | Added | Mar 2026 |
| 20 | Adar1 Capital Management, Llc | 135,560 | $2M | New | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$746.3M
Enterprise Value
$467.6M
P/E (TTM)
-9.27x
Forward P/E
—
PEG Ratio
0.09x
P/B
2.74x
P/S
82.97x
P/FCF
-9.06x
EV/EBITDA
—
Shares Out
35.9M
Financials (TTM)
Revenue
$9.0M
Net Income
-$80.6M
EBITDA
-$92.8M
Free Cash Flow
-$82.3M
Op Cash Flow
-$81.6M
EPS Basic
$-2.24
EPS Diluted
$-2.24
EPS Forward
$-2.68
Gross Margin
100.0%
Op Margin
-1031.5%
Net Margin
-896.1%
Balance Sheet
Total Assets
$294.9M
Total Liab.
$22.8M
Total Equity
$272.1M
Cash
$281.1M
LT Debt
$2.3M
Book Value/Sh
$7.57
Debt/Equity
0.02x
Current Ratio
14.24
Quick Ratio
14.24
Returns & Growth
ROE
-29.6%
ROA
-27.3%
ROIC
-33.4%
Rev Growth YoY
+0.0%
EPS Growth YoY
+66.2%
Price Returns
2W
-7.6%
1M
+2.6%
3M
-22.4%
6M
+82.2%
12M
+336.6%
Technicals
52W High
$22.92
52W Low
$4.12
50d MA
$17.38
200d MA
$14.00
RSI (14)
66.40
ATR (14)
$1.34
Beta
1.83
Avg Volume
431K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$45.00
High
$62.00
Low
$23.00
Median
$50.00
Data updated apr 24, 2026 9:40pm
· Source: financialmodelingprep.com